. Author manuscript; available in PMC: 2022 Nov 1.

Published in final edited form as: Adv Drug Deliv Rev. 2021 Sep 13;178:113971. doi: 10.1016/j.addr.2021.113971

Table 5.

Local delivery strategies for cell-based approaches to restore immune homeostasis from inflammation.

Cell-Based Approaches		Delivery Strategy	Disease Model	Ref(s)
Ex vivo isolation/delivery of regulatory subtypes
Dendritic cells		PEG hydrogels	Multiple sclerosis	[42]
Regulatory T cells		Alginate-GelMA hydrogels	Islet transplantation	[90]
Regulatory T cells		PEGNB hydrogels	Peripheral nerve allotransplantation	[71]
Mesenchymal stem cells		Dextran-PEG hydrogels	Islet transplantation	[221]
		Silk hydrogels	Islet transplantation	[111]
		PEO/Alginate MPs	Systemic lupus erythematosus	[222]
In situ engineering of endogenous subtypes
Dendritic Cells	GM-CSF, dexamethasone, peptidoglycan	Gelatin MPs	Ex vivo autoimmunity	[110]
	Tacrolimus, clondronate liposomes	PLGA MPs/Matrigel	Islet transplantation	[227]
	Rapamycin, retinoic acid, IL-10, TGF-β1	PLGA MPs	Ex vivo autoimmunity	[229]
Macrophages	CCL2	PLGA MPs	Periodontitis	[232]
Regulatory T cells	Anti-CD3/CD28, TGF-β1	PLGA/PBAE MPs	-	[233]
	TGF-β1, rapamycin, IL-2	PLGA MPs	-	[234]
	TGF-β1, rapamycin, IL-2	PLGA MPs	Contact dermatitis	[235]
	TGF-β1, rapamycin, IL-2	PLGA/PEG-PLGA MPs	Dry eye disease	[236]
	TGF-β1, rapamycin, IL-2	PLGA MPS	Vascularized composite allotransplantation	[30]
	TGF-β1, rapamycin, IL-2	PLGA/PEG-PLGA MPs	Inflammatory arthritis	[190]